A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
Condition: Cytomegalovirus Infection Interventions: Biological: mRNA-1647; Biological: Placebo Sponsor: ModernaTX, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials